The lyophilization process plays a crucial role in maintaining the stability of products that cannot be stored in liquid form.
Akums Drugs & Pharmaceuticals Ltd. on Thursday announced its new sterile manufacturing facility, dedicated to producing lyophilized products. In addition to lyophilized injectables, the facility is equipped to manufacture vials, ampoules, Form-Fill-Seal (FFS) products, and eye and ear drops, the company said in a statement.
This strategic expansion marks a pivotal step in Akums’ growth journey, significantly enhancing its sterile dosage capabilities. With advanced technology and increased production capacity, the facility positions Akums to meet the rising global demand and support large-scale manufacturing across a wide range of therapeutic areas.
“The global lyophilized injectables market, estimated at a value of approximately $3,365.4 million in 2023, is expected to experience steady growth, reaching an impressive $4,978.3 million by 2030. With a compound annual growth rate (CAGR) of 5.6% during the forecast period, this market demonstrates strong potential driven by increasing demand for products requiring enhanced stability and extended shelf life. As a niche segment with high entry barriers and limited competition, it presents significant opportunities to innovate and cater to specialized therapeutic needs. This growth highlights the strategic importance of investing in lyophilization capabilities,” the company said in a statement.
How Microsoft plans to reduce dependency on OpenAI
Whirlpool, PG Electroplast enters into agreement for contract manufacturing of select Whirlpool branded washing machines
MTNL assets to be maintained by borrowing from BSNL
Micromax and Taiwan’s Phison form JV to make storage chips in India
The facility, which is now operational, is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products across various therapeutic categories. Lyophilization is a crucial process in preserving the stability and shelf life of pharmaceutical products, especially for sensitive chemical compounds. By entering this space, Akums aims to meet the growing global demand for these products. Akums’ lyophilization facility offers a robust production capacity and the flexibility to handle multiple vial sizes, ensuring it can cater to a broad range of healthcare needs, it added.
“We are excited to announce our entry into lyophilized injectables, marking a significant milestone in our journey to provide world-class pharmaceutical solutions,” said Mr. Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd. “As global demand for lyophilized drugs continues to grow, our new facility is primed to meet this demand with the highest standards of quality and safety.”
The lyophilization process plays a crucial role in maintaining the stability of products that cannot be stored in liquid form. Akums’ new facility will support this essential need, serving many therapeutic areas and contribute to better patient outcomes, marking a positive step towards improved healthcare solutions.
According to the company’s statement, the facility adheres to stringent global quality standards, ensuring all products meet international regulatory requirements.